Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
Opinions Brett Girard, CPA, CA, CFA
Coloplast A/SCLPBYTOP PICKJan 13, 2020
A Danish healthcare company that focuses on wound care, skin care, digestion and other areas. Smart managers continue to focus on R&D--he likes that. Since 2015, they've increased clinical studies by 2.5x and patents by 10x. They've spent free cash flow very well. Revenues have grown 9% annually even during the Great Recession. (Analysts’ price target is $10.74)
N/A
Stock price when the opinion was issued
$5.75
As of Jun 18, 2026. Market Open.
Healthcare
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
TOP PICK
Makes catheters and colostomy bags. Elective surgeries are coming back. During pandemic, these were paused and medical device companies suffered. Their balance sheet is pristine. Number one in their business. Generate ROC close to 38%. Cost of capital is 6%. Room for R&D to move forward.
David DriscollOwned
Healthcare
PAST TOP PICK
(A Top Pick August 21/17, Up 24%) Colostomy bags and catheters, playing the aging demographic. Gained market share in US. Free cash flow is above competitors. Dividend grows about 10-15% per year. Investors go here to hide, so it goes up when markets go down. Buy on a pullback.
David DriscollOwned
Healthcare
TOP PICK
Colostomy bags. The demographics are such that gastrointestinal disorders are among the bigger problems dealing with the retirees of the world. If you get a company this size growing this fast without acquisitions you have a good company. They have a history of dividend increases. (Analysts’ target: DKK 553.00).
David DriscollOwned
Healthcare
